PolarityTE, Inc. (PTE)
| Market Cap | 7.10M |
| Revenue (ttm) | 5.44M |
| Net Income (ttm) | -16.55M |
| Shares Out | 4.46M |
| EPS (ttm) | -6.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,310 |
| Open | 1.61 |
| Previous Close | 1.58 |
| Day's Range | 1.59 - 1.68 |
| 52-Week Range | 1.41 - 23.00 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 24.23 (+1,423.9%) |
| Earnings Date | Aug 11, 2022 |
About PTE
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision,... [Read more...]
Financial Performance
In 2021, PolarityTE's revenue was $9.40 million, a decrease of -7.13% compared to the previous year's $10.13 million. Losses were -$30.19 million, -29.56% less than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PTE stock is "Buy." The 12-month stock price forecast is 24.23, which is an increase of 1,423.90% from the latest price.
News
PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq...
SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into s...
PolarityTE to Attend H.C. Wainwright Global Investment Conference
SALT LAKE CITY , May 23, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will prese...
PolarityTE to Effectuate 1-for-25 Reverse Stock Split
SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will effec...
PolarityTE, Inc. (PTE) Reports Q1 Loss, Misses Revenue Estimates
PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of -25% and 12.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update
PolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regene...
PTE Stock Soars 70% Following PolarityTE's New FDA Designation
PolarityTE (PTE) stock is rocketing higher on Friday thanks to positive news from the U.S. Food and Drug Administration (FDA). The post PTE Stock Soars 70% Following PolarityTE's New FDA Designation app...
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®
SALT LAKE CITY , May 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) desi...
PolarityTE to Report Q1 2021 Financial Results on May 16, 2022
SALT LAKE CITY , May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 1...
10 Top Penny Stocks To Buy For Under $1 May 2022 Edition
Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in...
SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational us...
Penny Stocks to Buy For Your Watchlist Next Week
Check these three penny stocks out for your watchlist right now The post Penny Stocks to Buy For Your Watchlist Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...
Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April
Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?
PTE Stock Is Rocketing Nearly 100% Today. It's About Time.
PolarityTE has finally gained the traction that it deserves in the midst of an inflection point for the company. The post PTE Stock Is Rocketing Nearly 100% Today.
Why Is PolarityTE Stock Up 85% Today?
PolarityTE Inc (NASDAQ: PTE) shares are surging Tuesday as traders circle bullish commentary from a popular trader in the "FinTwit" community. "FinTwit" is an abbreviated term for "Financial Twitter," w...
Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?
Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.
Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open
Here's what you need to know about buying penny stocks on April 12th The post Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open appeared first on Penny Stocks to Buy, Picks, News and ...
3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes
Check these three penny stocks out as PHIO stock climbs The post 3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
PolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET SALT LAKE CITY , March 30, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing re...
PolarityTE Announces Closing of $5.0 Million Registered Direct Offering
SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today ann...
PolarityTE Announces $5.0 Million Registered Direct Offering
SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today ann...
PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022
SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2...
PolarityTE's SkinTE Meets Primary, Secondary Goals In Venous Leg Ulcers Trial
PolarityTE Inc (NASDAQ: PTE) has announced results from a multi-center randomized controlled trial evaluating SkinTE for Venous Leg Ulcers (VLU). There were twenty-nine participants, with 14 receiving S...
PolarityTE Announces Allowance of Fourth U.S. Patent
SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Tradem...
PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study
PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.
FDA Approves PolarityTE's Phase 3 Study Of SkinTE In Chronic Cutaneous Ulcer
The FDA has signed off PolarityTE Inc's (NASDAQ: PTE) investigational new drug (IND) application to evaluate SkinTE to treat chronic cutaneous ulcers. This follows the Company satisfactorily addressing...